PDCD1 and melanoma: This approval was followed by the FDA’s endorsement of anti-programmed cell death protein 1 (PD-1) antibodies pembrolizumab and nivolumab in 2014, marking further advancements in immunotherapeutic options for melanoma treatment (11, 12).